Reduce DVT Risk With Synchronized Flow Technology

The ActiveCare +S.F.T. System is a portable, ambulatory, sequential intermittent pneumatic compression device (IPCD). The system includes a rechargeable battery allowing patient mobility and ease of use.

S.F.T. is a proprietary technology that determines the venous phasic flow of each patient and synchronizes compression to the patient’s individual flow pattern.

ActiveCare + S.F.T.System Flow Chart

ActiveCare Can Take Your Patients From Hospital to Home

Once patients are discharged from the hospital, they will receive the same, trusted preventative therapy. The ActiveCare+S.F.T. System is small and portable, allowing for patient mobility. Additionally, the ActiveCare system routinely monitors patient compliance, providing patients, caregivers and physicians with real time information.


Why Use ActiveCare+S.F.T.?

  • Safe and effective way to prevent DVT1,2,3
  • Clinically proven, without side effects such as serious bleeding complications5
  • Non-invasive DVT preventative treatment with high efficacy2,3 and safety1 profile, with no required blood draw at home
  • Small, portable and can be worn during normal daily activities and while you sleep, providing continuous therapy
  • Convenient and easy to return the device after prescribed use
  • Customer Care available 24/7
  1. Colwell, C.W. Jr., Froimson M.I., Mont M.A., Ritter M.A., Trousdale R.T., Buehler K.C., Spitzer A., Donaldson T.K., Padgett D.E. Thrombosis prevention after total hip arthroplasty: a prospective, randomized trial comparing a mobile compression device with LMWH. J Bone Joit Surg AM 2010; 92 (3): 527-535
  2. Colwell, C.W. Jr., Froimson M.I. Anseth, S.D., Giori, N.J, Hamilton, W.G, Barrack, R.L., Buehler, K.C., Mont, M.A; Padgett, D.E., Pulido P.A.; and Barnes, C.L., Thrombosis Prevention Using a Portable Compression Device as Monotherapy in Hip and Knee Arthroplasty. J. Bone Joint Surg Am, 2014 Feb 05; 96 (3): 177-183
  3. Gelfer Y., Tavor H., Oron A. et al., Deep Vein Thrombosis prevention in joint arthroplasties: continuous enhanced circulation therapy vs LMWH. J Arthroplasty 2006;21(2):206-14
All content herein is protected by copyright, trademarks and other intellectual property rights, as applicable, owned by or licensed to Zimmer Biomet or its affiliates unless otherwise indicated, and must not be redistributed, duplicated or disclosed, in whole or in part, without the express written consent of Zimmer Biomet. This material is intended for health care professionals.  Distribution to any other recipient is prohibited. For product information, including indications, contraindications, warnings, precautions, potential adverse effects and patient counselling information, see the package insert and